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Abstract
Patient Acceptable Symptom State (PASS) is an absolute
threshold proposed for symptomatic variables in osteoarthritis
(OA) to determine the point beyond which patients consider
themselves well and, as such, are satisfied with treatment. Two
large previously reported studies of knee OA have shown that
both lumiracoxib and celecoxib were superior to placebo in
terms of conventional outcome measures. To assess the clinical
relevance of these results from the patient's perspective, the
same data pooled from these two studies were analysed with
respect to the PASS. In total, 3,235 patients were included in
two multicentre, randomised, double-blind studies of identical
design. Patients were randomly assigned to receive lumiracoxib
100 mg once daily (n = 811), lumiracoxib 100 mg once daily
with an initial dose of lumiracoxib 200 mg once daily for the first
2 weeks (100 mg once daily with initial dose [n = 805]),
celecoxib 200 mg once daily (n = 813), or placebo (n = 806)
for 13 weeks. Treatments were compared with respect to the
PASS criteria (for OA pain, patient's global assessment of
disease activity, and the Western Ontario and McMaster
Universities Osteoarthritis Index Likert version 3.1 [WOMAC™
LK 3.1] Function [difficulty in performing daily activities]
subscale score). At week 13, 43.3%, 45.3%, and 42.2% of
patients in the lumiracoxib 100 mg once daily, lumiracoxib 100
mg once daily with initial dose, and the celecoxib 200 mg once
daily groups, respectively, considered their current states as
satisfactory versus 35.5% in the placebo group. Similar results
were observed for patient's global assessment of disease
activity and WOMAC™ LK 3.1 Function subscale score. This
post hoc analysis suggests that the statistical significance of the
results observed with lumiracoxib or celecoxib compared with
placebo using conventional outcome variables is complemented
by clinical relevance to the patient. Trial registration numbers:
NCT00366938 and NCT00367315.
Introduction
In 2003, the Outcome Measures in Clinical Trials (OMERACT)
6 meeting emphasised the importance of defining clinical trial
outcomes that are comprehensive and can be used to influ-
ence clinical decision-making [1]. The question for many clini-
cians is whether changes in self-reported levels of pain on a 0-
to 100-mm visual-analogue scale (VAS) are clinically impor-
tant and whether they reflect a meaningful improvement for the
patient. Clinicians strongly favour the presentation of results at
an individual level rather than a group level (as expressed by
the mean change in symptom score) [2]. The challenge of the
meeting was to determine the minimal meaningful change in a
score for an individual by means of a structured instrument.Page 1 of 11
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the patient's perspective have recently been developed and
tested for clinical trials. These two concept measures are the
Minimal Clinically Important Improvement (MCII), defined as
the smallest change in a measurement which signifies an
important improvement in a patient's symptom score [3], and
the Patient Acceptable Symptom State (PASS), defined as
the symptom score beyond which patients consider them-
selves to be well [2,4,5]. These measures are complementary,
describing, from the patient's perspective, the concept of well-
being or remission of symptoms: that is, 'feeling good' (encom-
passed in PASS) and the concept of improvement or 'feeling
better' (encompassed in MCII) [2].
PASS provides clinically meaningful information that can be
expressed as a percentage of patients who meet the threshold
for PASS regardless of the change from baseline in symp-
toms. PASS thresholds (on a 0- to 100-mm VAS) have
recently been proposed for patients with osteoarthritis (OA) of
the knee. These were less than or equal to 32.3 mm for pain
intensity, less than or equal to 32.0 mm for patient's global
assessment of disease activity, and a score of less than or
equal to 31.0 for Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC™) Function (difficulty in per-
forming daily activities) subscale score [5]. The VAS version of
the WOMAC™ Function subscale must be converted to a 0-
to 68-point scale if the Likert version 3.1 (LK 3.1) of the
WOMAC™ questionnaire is used: the PASS threshold of less
than or equal to 31.0 then converts into a threshold of less
than or equal to 21.08, which must be achieved for a patient
to be satisfied according to PASS. Assessment of patient sat-
isfaction by means of the PASS criteria can be approached in
a number of ways: satisfaction at the end of a study period,
time taken to achieve patient satisfaction, or time taken to
achieve sustained satisfaction. Time taken to achieve patient
satisfaction provides an evaluation not only of the concept of
'feeling good' but also of 'feeling good as soon as possible.'
Time taken to achieve sustained satisfaction combines the
concept of 'feeling good as soon as possible' with the general
definition of 'good condition,' thus providing a measurement of
sustained good condition; it is defined as the first visit during
which the value of the variable exceeds the PASS criteria and
remains so until study end. In studies that incorporate a
number of scheduled visits before the final one, for both time
taken to achieve satisfaction and time taken to achieve sus-
tained satisfaction, the Kaplan-Meier method can be used and
the results presented using a Kaplan-Meier analysis.
In parallel to the development of the PASS criteria, MCII
thresholds for absolute change in pain intensity, patient's glo-
bal assessment of disease activity, and WOMAC™ Function
subscale score in patients with OA of the knee (defined as the
75th percentile of the change in score among patients whose
evaluation of response to treatment was 'good') were reported
as -19.9, -18.3, and -9.1 mm, respectively [3]. As for PASS,
the VAS version of the WOMAC™ Function subscale must be
converted to a 0- to 68-point scale if the LK 3.1 version of the
WOMAC™ questionnaire is used; the -9.1-mm MCII threshold
then converts into a -6.19 threshold, which must be achieved
for a patient to be satisfied according to MCII. The PASS and
MCII thresholds have subsequently been used to facilitate the
presentation and interpretation of results obtained in clinical
trials [4].
Lumiracoxib is a novel, selective cyclo-oxygenase-2 (COX-2)
inhibitor for the treatment of OA and acute pain. In two 13-
week, international, multicentre, double-blind studies in
patients with OA of the knee, it was compared with celecoxib
200 mg once daily (od) as a positive control and placebo as a
negative control. Both lumiracoxib 100 mg od and celecoxib
200 mg od demonstrated a statistically significant improve-
ment in OA symptoms compared with placebo when analysing
conventional outcome variables (OA pain, patient's global
assessment of disease activity, and the WOMAC™ question-
naire total score) [6,7].
Here, we report on a pooled analysis of the above two studies.
This analysis evaluated the effectiveness of lumiracoxib 100 m
god (with and without a 200-mg od initial dose for the first 2
weeks) and celecoxib 200 mg od compared with placebo
according to the percentage of patients achieving PASS or
MCII thresholds for OA pain, patient's global assessment of
disease activity, and functional impairment. We present data
on patient satisfaction according to PASS during and at the
end of the study period and on patient achievement of sus-
tained satisfaction by PASS.
Materials and methods
A pooled analysis of data taken from two international, multi-
centre, double-blind, double-dummy, placebo-controlled, par-
allel-group, 13-week studies of patients with OA of the knee
and of identical design was conducted. Methodology for the
studies has previously been described elsewhere in detail
[6,7] and both studies were registered by Clinical Trials [8]
(registration numbers NCT00366938 and NCT00367315).
Assessments and variables
The co-primary efficacy variables were OA pain intensity in the
target knee, patient's global assessment of disease activity,
and functional status (WOMAC™ LK 3.1 subscale) measured
at study end [6,7]. Post-baseline clinic visits were at weeks 2,
4, 8, and 13 [6,7]. At any visit during the study, achievement
of symptom satisfaction for OA pain, patient's global assess-
ment of disease activity, and WOMAC™ LK 3.1 Function
score was assessed by the percentage of patients achieving
PASS.
Statistical analysis
Unless otherwise stated, evaluations were performed on an
intention-to-treat basis, which included all patients who hadPage 2 of 11
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medication. In the event of missing data, the last-observation-
carried-forward technique was used. For dichotomous varia-
bles, the number needed to treat (NNT) (that is, the number of
patients needed to be treated with the active treatment rather
than placebo for one additional patient to benefit) was derived
from the difference in response rates between active treat-
ment and placebo.
By means of a conventional approach, the treatment effect
(that is, each active treatment group versus placebo) for the
three symptomatic outcome variables – OA pain, patient's glo-
bal assessment of disease activity, and WOMAC™ LK 3.1
Function – was originally estimated using the least square
means obtained from an analysis of covariance with study and
baseline values as covariates.
Table 1
Patient demographics and baseline disease characteristics
Lumiracoxib 100 mg od
(n = 811)
Lumiracoxib 100 mg od 
with initial dose
(n = 805)




Age in years, mean ± SD 61.3 ± 10.6 61.9 ± 10.3 61.6 ± 10.6 61.3 ± 10.4
Females, n (%) 526 (64.9) 539 (67.0) 535 (65.8) 539 (66.9)
Body mass index in kg/m2, 
mean ± SD
31.2 ± 6.3 31.2 ± 6.1 31.1 ± 6.5 31.1 ± 6.2
Race, n (%)
Caucasian 773 (95.3) 755 (93.8) 756 (93.0) 765 (94.9)
Black/African-American 19 (2.3) 20 (2.5) 30 (3.7) 19 (2.4)
Disease duration in years, 
mean ± SD
5.6 ± 6.8 5.6 ± 7.3 5.5 ± 6.9 5.4 ± 6.6
Baseline OA pain intensity 
(VAS [mm])
65.2 (13.8) 64.9 (13.7) 65.6 (13.8) 64.9 (13.2)
Baseline patient's global 
assessment of disease 
activity (VAS [mm])
63.1 (17.2) 62.7 (17.1) 62.3 (17.7) 62.7 (16.6)
Baseline WOMAC™ LK 
3.1 Function score (VAS)
36.2 (10.8) 36.4 (11.3) 36.6 (10.9) 36.5 (10.7)
OA, osteoarthritis; od, once daily; SD, standard deviation; VAS, visual-analogue scale; WOMAC™ LK 3.1, Western Ontario and McMaster 
Universities Osteoarthritis Index Likert version 3.1.
Figure 1
Patient flow diagram.Page 3 of 11
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bles (yes/no) with regard to the MCII and PASS criteria. The
percentage of patients achieving improvement according to
MCII was assessed at weeks 2, 4, 8, and 13 for OA pain inten-
sity in the target knee (change greater than or equal to 19.9
mm on VAS) and patient's global assessment of disease activ-
ity (change greater than or equal to 18.3 mm on VAS) and at
weeks 2, 8, and 13 for WOMAC™ LK 3.1 Function subscale
score (change greater than or equal to 6.19 [converted from
VAS]) [3]. The percentage of patients achieving symptom sat-
isfaction according to PASS was assessed at weeks 2, 4, 8,
and 13 for OA pain intensity in the target knee (less than or
equal to 32.3 mm on VAS) and patient's global assessment of
disease activity (less than or equal to 32.0 mm on VAS) and at
weeks 2, 8, and 13 for the WOMAC™ LK 3.1 Function sub-
scale score (less than or equal to 21.08 [converted from
VAS]) [5]. For these variables, the treatment effect was evalu-
ated by fitting a multiple logistic regression model with treat-
ment as the main effect. Pairwise comparisons between
treatment effects were based on the likelihood ratio tests from
type III analyses. Odds ratios for the between-treatment com-
parisons were also presented.
For each PASS variable, the Kaplan-Meier method was used
to estimate the time to achievement of first sustained PASS,
defined by the first time (first visit) that the PASS threshold
(32.3 mm for pain, 32.0 mm for patient's global assessment of
disease activity, and 21.08 for WOMAC™ LK 3.1 Function)
Table 2
OA pain intensity
Lumiracoxib 100 mg od
(n = 811)
Lumiracoxib 100 mg od 
with initial dose
(n = 805)




Mean change from 
baseline at week 2 ± SDa
-20.1b ± 21.97 -20.9b ± 22.50 -20.2b ± 21.86 -12.1 ± 19.92
Mean change from 
baseline at week 13 ± SDa
-26.0b ± 24.83 -26.0b ± 24.92 -25.4b ± 25.03 -19.8 ± 24.75
Response by MCIIa
Responders at week 2, n 
(%)
383 (47.2) 378 (47.0) 392 (48.3) 254 (31.6)
Odds ratio versus 
placeboc (95% CI)
1.94b (1.58–2.38) 1.92b (1.57–2.35) 2.02b (1.65–2.48) NA
Odds ratio versus 
celecoxibc (95% CI)
0.96d (0.79–1.17) 0.95d (0.78–1.15) NA NA
Responders at week 13, n 
(%)
484 (59.7) 489 (60.7) 463 (57.0) 393 (48.8)
Odds ratio versus 
placeboc (95% CI)
1.55b (1.27–1.89) 1.62b (1.33–1.98) 1.39b (1.14–1.69) NA
Odds ratio versus 
celecoxibc (95% CI)
1.12d (0.92–1.36) 1.17d (0.96–1.42) NA NA
Patients considering their current state as satisfactory by PASSe
Satisfied patients at week 
2, n (%)
251 (30.9) 270 (33.5) 242 (29.8) 137 (17.0)
Odds ratio versus 
placeboc (95% CI)
2.19b (1.73–2.77) 2.46b (1.95–3.12) 2.07b (1.63–2.62) NA
Odds ratio versus 
celecoxibc (95% CI)
1.06d (0.86–1.31) 1.19d (0.97–1.47) NA NA
Satisfied patients at week 
13, n (%)
351 (43.3) 365 (45.3) 343 (42.2) 286 (35.5)
Odds ratio versus 
placeboc (95% CI)
1.39b (1.14–1.70) 1.51b (1.23–1.84) 1.33f (1.09–1.62) NA
Odds ratio versus 
celecoxibc (95% CI)
1.05d (0.86–1.27) 1.14d (0.93–1.38) NA NA
aA patient was considered a responder by MCII if his/her change from baseline for OA pain intensity was decreased by greater than or equal to 
19.9 mm. bp < 0.001 versus placebo. cMultiple logistic regression model with treatment as main effect. Pairwise comparisons were tested using 
two-sided significance unadjusted for multiple comparisons. dp value non-significant. eA patient was considered as achieving a satisfactory state 
according to PASS if his/her value for OA pain intensity was less than or equal to 32.3 mm. fp < 0.01 versus placebo. CI, confidence interval; 
MCII, Minimal Clinically Important Improvement; NA, not applicable; OA, osteoarthritis; od, once daily; PASS, Patient Acceptable Symptom State; 
SD, standard deviation.Page 4 of 11
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tive visits until week 13 (inclusive). Missing data were not
imputed. Only patients with consecutive visits up to week 13
and with no values of the variable missing or above the PASS
threshold at week 13 were considered to have achieved a sus-
tained PASS; otherwise, patients were considered censored
at the last date on treatment. The results are presented using
Kaplan-Meier curves, and the pairwise comparisons between
treatment effects were evaluated using Wilcoxon tests.
The percentage of patients achieving the threshold for at least
one, two, or three PASS criteria (OA pain, patient's global
assessment of disease activity, or WOMAC™ LK 3.1 Function
subscale score) was calculated at weeks 2 and 13.
Finally, response to treatment according to the OMERACT-
Osteoarthritis Research Society International (OMERACT-
OARSI) criteria was assessed at weeks 2, 8, and 13 [6,7]. A
logistic regression model was used to analyse responses to
treatment according to OMERACT-OARSI criteria.
Results
Patient demographics and baseline disease characteristics of
the 3,235 patients included in the pooled analysis are shown
in Table 1. A patient flow diagram is shown in Figure 1.
Evaluation of each outcome variable according to 
different techniques
Final visit of the study
Tables 2 to 4 summarise mean changes from baseline,
patients achieving the MCII threshold, and patients achieving
the PASS threshold for OA pain (Table 2; Figure 2a), the
patient's global assessment of disease activity (Table 3; Figure
3a), and WOMAC™ Function subscale score at week 13
(Table 4; Figure 4a).
For each variable (OA pain, patient's global assessment of dis-
ease activity, and the WOMAC™ Function subscale score),
each of the analysis methods showed statistically significant
superiority of lumiracoxib 100 mg od (with or without initial
dose) or celecoxib 200 mg od to placebo (Table 2). Moreover,
the observed treatment effect (for example, the difference in
the percentage of patients in the active treatment minus pla-
Table 3
Patient's global assessment of disease activity
Lumiracoxib 100 mg od
(n = 811)
Lumiracoxib 100 mg od 
with initial dose
(n = 805)




Mean change from baseline at week 2 
± SDa
-18.4b ± 23.62 -19.0b ± 23.83 -17.1b ± 23.72 -9.5 ± 20.81
Mean change from baseline at week 
13 ± SDa
-24.2b ± 25.83 -23.2b ± 25.57 -21.3b ± 26.78 -16.3b ± 25.19
Response by MCIIc at week 13
Responders at week 2, n (%) 359 (44.3) 369 (45.8) 352 (43.3) 242 (30.1)
Odds ratio versus placebod (95% CI) 1.85b (1.51–2.27) 1.97b (1.60–2.42) 1.78b (1.45–2.18) NA
Odds ratio versus celecoxibd (95% CI) 1.04e (0.85–1.27) 1.11e (0.91–1.35) NA NA
Responders at week 13, n (%) 465 (57.3) 456 (56.6) 432 (53.1) 357 (44.3)
Odds ratio versus placebod (95% CI) 1.69b (1.39–2.05) 1.64b (1.35–2.00) 1.42b (1.17–1.73) NA
Odds ratio versus celecoxibd (95% CI) 1.19e (0.97–1.44) 1.15e (0.95–1.40) NA NA
Satisfaction with treatment by PASSf
Satisfied patients at week 2, n (%) 240 (29.6) 255 (31.7) 234 (28.8) 140 (17.4)
Odds ratio versus placebod (95% CI) 2.00b (1.58–2.53) 2.21b (1.74–2.79) 1.92b (1.52–2.44) NA
Odds ratio versus celecoxibd (95% CI) 1.04e (0.84–1.29) 1.15e (0.93–1.42) NA NA
Satisfied patients at week 13, n (%) 347 (42.8) 353 (43.9) 321(39.5) 255 (31.6)
Odds ratio versus placebod (95% CI) 1.62b (1.32–1.98) 1.69b (1.38–2.07) 1.41b (1.15–1.73) NA
Odds ratio versus celecoxibd (95% CI) 1.15e (0.94–1.40) 1.20e (0.98–1.46) NA NA
ap values for comparison with placebo in analysis of covariance adjusting for study and baseline. bp < 0.001 versus placebo. cA patient was 
considered a responder by MCII if his/her change from baseline for patient's global assessment was decreased by greater than or equal to 18.3 
mm. dMultiple logistic regression model with treatment as main effect. Pairwise comparisons were tested using two-sided significance unadjusted 
for multiple comparisons. ep value non-significant. fA patient was considered as achieving a satisfactory state according to PASS if his/her value 
for patient's global assessment was less than or equal to 32.0 mm. CI, confidence interval; MCII, Minimal Clinically Important Improvement; NA, 
not applicable; od, once daily; PASS, Patient Acceptable Symptom State; SD, standard deviation.Page 5 of 11
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is usually considered as reflecting a clinical relevance of the
results. No statistical differences were observed between
lumiracoxib 100 mg od (with or without initial dose) and
celecoxib for any of the variables analysed.
For OA pain, the corresponding NNTs (95% confidence inter-
vals [CIs]) for the active treatments at week 13 were 12.8
(7.97 to 32.80), 10.1 (6.84 to 19.65), and 14.9 (8.74 to
50.79) for lumiracoxib 100 mg od, lumiracoxib 100 mg od with
initial dose, and celecoxib 200 mg od, respectively.
For patient's global assessment of disease activity, the corre-
sponding NNTs (95% CIs) for the active treatment groups at
week 13 were 9.0 (6.32 to 15.46), 8.2 (5.91 to 13.30), and
12.7 (8.00 to 31.27) for lumiracoxib 100 mg od, lumiracoxib
100 mg od with initial dose, and celecoxib 200 mg od,
respectively.
For the WOMAC™ Function subscale score, the correspond-
ing NNTs (95% CIs) for all active treatment groups at week 13
were 8.3 (6.00 to 13.52), 8.4 (6.05 to 13.79), and 10.8 (7.24
to 21.65) for lumiracoxib 100 mg od, lumiracoxib 100 mg od
with initial dose, and celecoxib 200 mg od, respectively.
Early effect at 2 weeks
Significantly more patients were satisfied with treatment as
defined by MCII or PASS in the lumiracoxib 100 mg od, lumi-
Table 4
WOMAC™ LK 3.1 Function subscale score response
Lumiracoxib 100 mg od
(n = 811)
100 mg od with initial dose
(n = 805)




Mean change from 
baseline at week 2 ± SDa
-8.7b ± 10.71 -8.9b ± 11.19 -8.7b ± 10.61 -4.1 ± 9.41
Mean change from 
baseline at week 13 ± SDa
-11.2b ± 12.65 -11.2b ± 12.71 -10.5b ± 12.41 -7.2 ± 12.62
Response by MCIIc
Responders at week 2, n 
(%)
425 (52.7) 413 (51.7) 422 (52.1) 264 (32.9)
Odds ratio versus 
placebod (95% CI)
2.27b (1.86–2.78) 2.18b (1.78–2.67) 2.22b (1.81–2.72) NA
Odds ratio versus 
celecoxibd (95% CI)
1.02e (0.84–1.24) 0.98e (0.81–1.20) NA NA
Responders at week 13, n 
(%)
506 (62.7) 495 (62.0) 490 (60.5) 378 (47.1)
Odds ratio versus 
placebod (95% CI)
1.89b (1.55–2.31) 1.83b (1.50–2.23) 1.72b (1.41–2.10) NA
Odds ratio versus 
celecoxibd (95% CI)
1.10e (0.90–1.34) 1.06e (0.87–1.30) NA NA
Patients considering their current state as satisfactory by PASSf
Satisfied patients at week 
2, n (%)
262 (32.3) 271 (33.7) 259 (31.9) 154 (19.1)
Odds ratio versus 
placebod (95% CI)
2.02b (1.61–2.54) 2.15b (1.71–2.71) 1.98b (1.57–2.49) NA
Odds ratio versus 
celecoxibd (95% CI)
1.02e (0.83–1.26) 1.09e (0.88–1.34) NA NA
Satisfied patients at week 
13, n (%)
337 (41.6) 333 (41.4) 315 (38.7) 238 (29.5)
Odds ratio versus 
placebod
1.70b (1.38–2.09) 1.69b (1.37–2.07) 1.51b (1.23–1.86) NA
Odds ratio versus 
celecoxibd
1.12e (0.92–1.37) 1.12e (0.92–1.36) NA NA
ap values for comparison with placebo in analysis of covariance adjusting for study and baseline. bp < 0.001 versus placebo. cA patient was 
considered a responder by MCII if his/her change from baseline for WOMAC™ LK 3.1 Function was decreased by greater than or equal to 6.19 
(converted from VAS). dMultiple logistic regression model with treatment as main effect. Pairwise comparisons were tested using two-sided 
significance unadjusted for multiple comparisons. ep value non-significant. fA patient was considered as achieving a satisfactory state according to 
PASS if his/her value for WOMAC™ LK 3.1 Function was less than or equal to 21.08 (converted from VAS). CI, confidence interval; MCII, Minimal 
Clinically Important Improvement; NA, not applicable; od, once daily; PASS, Patient Acceptable Symptom State; SD, standard deviation; VAS, 
visual-analogue scale; WOMAC™ LK 3.1, Western Ontario and McMaster Universities Osteoarthritis Index Likert version 3.1.Page 6 of 11
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groups compared with those in the placebo group at week 2
(Tables 2, 3, 4, 5).
Achievement of sustained PASS during the study
Achievement of a sustained satisfactory symptom state
according to PASS, maintained from the clinic visit during the
study until the end of the study, is summarised in Figures 2b,
3b, and 4b for the three outcome measures, respectively. At all
time points, all the performed analyses showed statistically
significant differences in favour of lumiracoxib 100 mg od (with
or without initial dose) or celecoxib 200 mg od over placebo.
Achievement of PASS for multiple variables
Table 5 shows the percentage of patients who achieved a
PASS for one or more, two or more, and three variables at
week 13. A high proportion of patients receiving lumiracoxib
100 mg od (57.2%), lumiracoxib 100 mg od with initial dose
(59.4%), or celecoxib (54.5%) achieved a satisfactory symp-
tom state according to PASS for at least one of the three var-
iables evaluated.
Response by OMERACT-OARSI criteria
At all time points, a significantly greater number of patients in
the lumiracoxib 100 mg od, lumiracoxib 100 mg od with initial
Figure 2
Osteoarthritis pain intensity in the target knee. (a) Percentage of patients considering their state as satisfactory according to Patient Acceptable 
Symptom State (PASS) at weeks 2, 4, 8, and 13. **P < 0.01; ***P < 0.001 versus placebo logistic regression model adjusted for multiple compari-
sons. (b) Kaplan-Meier estimate of the probability of first sustained satisfaction with treatment maintained until week 13 according to PASS. P < 
0.001 versus placebo for all active treatments using both log-rank and Wilcoxon tests except for lumiracoxib with initial dose versus placebo using 
Wilcoxon (P < 0.0001).Page 7 of 11
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 No 1    Dougados et al.dose, and the celecoxib 200 mg od groups responded to
treatment as defined by the OMERACT-OARSI criteria com-
pared with placebo (Figure 5).
Discussion
This study suggests that the analysis of clinical trials evaluat-
ing quick-acting symptomatic drugs, such as nonsteroidal anti-
inflammatory drugs and selective COX-2 inhibitors, in OA can
be adequately performed not only by using a conventional
approach (for example, by comparing changes in conventional
outcome variables by treatment group during the study) but
also by referring to the novel concept of PASS.
The statistical analysis of continuous variables is usually con-
sidered as more powerful than the analysis of dichotomous
variables. The concept of PASS does necessitate a switch
from a continuous variable (for example, 0- to 100-mm VAS) to
a dichotomous variable (for example, acceptable state yes/no).
Despite such potential weakness, this study suggests that,
when evaluating active drugs such as lumiracoxib or celecoxib
Figure 3
Patient's global assessment of disease activity. (a) Percentage of patients considering their state as satisfactory according to Patient Acceptable 
Symptom State (PASS) at weeks 2, 4, 8, and 13. **P < 0.01; ***P < 0.001 versus placebo logistic regression model adjusted for multiple compari-
sons. (b) Kaplan-Meier estimate of the probability of first sustained satisfaction with treatment maintained until week 13 according to PASS. P < 
0.001 versus placebo for all active treatments using both log-rank and Wilcoxon tests.Page 8 of 11
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significance.
It is often difficult for clinicians to interpret clinical relevance of
results obtained using conventional approaches. The presen-
tation of the percentage of patients who consider themselves
to have an acceptable symptom state is therefore of great rel-
evance to clinicians and is a useful assessment variable in clin-
ical trials. Finally, such presentation facilitates the evaluation of
the reported placebo-controlled trials. In the case of
symptomatic treatment of OA, a 10-point difference between
the placebo group and the active group is usually considered
as clinically relevant (expert's opinion). Two previous studies
have shown that lumiracoxib 100 mg od (with or without initial
dose) and celecoxib 200 mg od were significantly better than
placebo for improving conventional measures of OA outcomes
in clinical trials [6,7]. These data were reanalysed for PASS,
and for all the evaluated variables, the observed treatment
effect of lumiracoxib 100 mg od with or without initial dose or
celecoxib 200 mg od over placebo was near or above the
expected 10-point difference, suggesting that observed
results are not only of statistical significance but also of clinical
Figure 4
Western Ontario and McMaster Universities Osteoarthritis Index Likert version 3.1i i i iti  I  i rt v r i  . . Function subscale score. (a) Percentage of patients considering 
their state as satisfactory according to Patient Acceptable Symptom State (PASS) at weeks 2, 8, and 13. ***P < 0.001 versus placebo logistic 
regression model unadjusted for multiple comparisons.(b) Kaplan-Meier estimate of the probability of first sustained satisfaction with treatment main-
tained until week 13 according to PASS. P < 0.001 versus placebo for all active treatments using both log-rank and Wilcoxon tests.Page 9 of 11
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showing that this concept also allows evaluation of efficacy
early in treatment.
A high proportion of patients in the active groups achieved an
acceptable state according to PASS for at least one measure
of symptom relief. Almost half of these patients achieved the
PASS threshold for all three measures. Fewer patients
achieved the PASS threshold than the MCII threshold. This dif-
ferentiation between the two endpoints implies that PASS is
an important new assessment measure in pain research.
Conclusion
This investigation found that a high proportion of patients with
OA of the knee, who were treated with lumiracoxib 100 mg od
or celecoxib 200 mg od, reported an acceptable symptom
state after 13 weeks for multiple measures. Studies of longer
Table 5
Patients achieving a satisfactory symptom state according to one or more, two or more, or three PASS criteriaa
Lumiracoxib 100 mg od
(n = 811)
Lumiracoxib 100 mg od 
with initial dose
(n = 805)




Patients considering their current state as satisfactory at week 2 according to:
One or more PASS 
criteria, n (%)
396 (48.8) 393 (48.8) 367 (45.1) 241 (29.9)
Two or more PASS 
criteria, n (%)
229 (28.2) 259 (32.2) 226 (27.8) 128 (15.9)
Three PASS criteria, n (%) 128 (15.8) 144 (17.9) 142 (17.5) 62 (7.7)
Patients considering their current state as satisfactory at week 13 according to:
One or more PASS 
criteria, n (%)
464 (57.2) 478 (59.4) 443 (54.5) 367 (45.5)
Two or more PASS 
criteria, n (%)
340 (41.9) 343 (42.6) 325 (40.0) 256 (31.8)
Three PASS criteria, n (%) 231 (28.5) 230 (28.6) 211 (26.0) 156 (19.4)
aOsteoarthritis pain, patient's global assessment of disease activity, or WOMAC™ LK 3.1 Function subscale score. od, once daily; PASS, Patient 
Acceptable Symptom State; WOMAC™ LK 3.1, Western Ontario and McMaster Universities Osteoarthritis Index Likert version 3.1.
Figure 5
Response to treatment according to criteria of Outcome Measures in Clinical Trials-Osteoarthritis Research Society International. ***P < 0.001 ver-
sus placebo logistic regression model unadjusted for multiple comparisons.Page 10 of 11
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evaluating different treatment modalities are still required to
further validate the PASS concept.
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